AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-15113027_ITM" title="Facts and information about RANBAXY TO LAUNCH SIMVASTATIN IN US AFTER USFDA NOD.">RANBAXY TO LAUNCH SIMVASTATIN IN US AFTER USFDA NOD.</a>
Close
Set up an RSS feed that alerts you when new articles from AsiaPulse News are available.
Frequently asked questions about RSS feeds
RANBAXY TO LAUNCH SIMVASTATIN IN US AFTER USFDA NOD.
NEW DELHI, May 3 Asia Pulse - The country's leading drugmaker Ranbaxy Laboratories Ltd (BSE:500359) on Tuesday said it will launch its Simvastatin drug after it gets the final nod from USFDA, whose rejection of the company's claims for exclusive marketing rights was set aside by a US court.
Simvastatin is a cholestrol lowering drug.
A district court in the US ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- New Delhi, Nov 3 (PTI) Ranbaxy Laboratories Limited (Ranbaxy) today said the UK...
- News wire article from: PTI - The Press Trust of India Ltd. November 3, 2005 700+ words
...decision on the other patent before the UK Court of Appeal," Ranbaxy Laboratories Ltd President & Executive Director Malvinder Singh said...outcome of both appeals is expected by the end of 2006. (THROUGH ASIA PULSE)
- Mumbai, Oct 10 (PTI) Ranbaxy Laboratories Ltd has received final approval from...
- News wire article from: PTI - The Press Trust of India Ltd. October 10, 2005 700+ words
...in the treatment of partial seizures with and without secondary generalization in epilepsy patients aged 12 and above, it said. It treats partial seizures in pediatric patients aged betw een 3-12 years, it added. (THROUGH ASIA PULSE)
- New Delhi, Oct 21 (PTI) Ranbaxy Laboratories today said it had initiated talks...
- News wire article from: PTI - The Press Trust of India Ltd. October 21, 2005 700+ words
...Roche had also confirmed that it was awaiting approval for its patent for Tamiflu in India. "It is pending," Roche's India head G L Telang said when asked to confirm the status of Tamiflu's patent in India. (THROUGH ASIA PULSE)
- New Delhi, Oct 7 (PTI) Ranbaxy Laboratories Limited (RLL) today said it has...
- News wire article from: PTI - The Press Trust of India Ltd. October 7, 2005 700+ words
...available through the innovator company. RPI will offer these tablet strengths as well as tablets of 3mg, 6mg and 8mg that are additional strengths developed through Ranbaxy's R&D organization, Krishnan added. (THROUGH ASIA PULSE)
- New Delhi, Sep 30 (PTI) Ranbaxy Laboratories Ltd has announced that the World...
- News wire article from: PTI - The Press Trust of India Ltd. September 30, 2005 700+ words
...Ranbaxy Managing Director Brien Tempest said. Nevirapine tablets are already approved by USFDA and are eligible for use in programmes funded by the US Presidents Emergency Plan for AIDS relief, the statement said. (THROUGH ASIA PULSE)
- New Delhi, Oct 27 (PTI) Ranbaxy Laboratories Ltd and the promoter group...
- News wire article from: PTI - The Press Trust of India Ltd. October 27, 2005 700+ words
...such as Fortis Healthcare Ltd, Fortis Securities Ltd and Escorts Health Institute and Research Centre Ltd have made this donation for the people affected due to earthquake that struck Kashmir on October eight, it said. (THROUGH ASIA PULSE)
- Mumbai, Oct 13 (PTI) Pharmaceutical major Ranbaxy Laboratories Ltd (RLL) today...
- News wire article from: PTI - The Press Trust of India Ltd. October 13, 2005 700+ words
...he added Florida based Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of the RLL, is engaged in the sale and distribution of generic and branded prescription products in the U.S. Healthcare system. (THROUGH ASIA PULSE)
- New Delhi, Oct 19 (PTI) Pharma major Ranbaxy laboratories Ltd has announced the...
- News wire article from: PTI - The Press Trust of India Ltd. October 19, 2005 700+ words
...drug against malaria," CEO and Managing Director Dr Brain Tempest said. The Company and MMV have jointly decided to progress the drug to Phase II dose range studies in India, Thailand and Africa, the company said. (THROUGH ASIA PULSE)
Source: HighBeam Research, RANBAXY TO LAUNCH SIMVASTATIN IN US AFTER USFDA NOD.